Search results for 'doxycycline manufacturers' often combine several kinds of companies: the holder of a drug approval, the NDC labeler, the distributor, a contract manufacturer and a repackager. These roles are not identical. A meaningful U.S. product check begins with the complete label and NDC rather than an unsourced list of supposedly leading factories.
Doxycycline adds another layer of complexity because hyclate and monohydrate, capsules and tablets, immediate- and delayed-release products, and special 40 mg rosacea capsules appear under closely related drug names. A company name alone cannot establish which formulation a pharmacy can actually dispense.
This guide explains how to investigate a specific product listing. For drug identity start with generic doxycycline options; for salt-level differences consult hyclate products and monohydrate products. The goal is label transparency, not a promotional manufacturer directory.
An application holder may own the approved marketing application; a labeler is the entity assigned the NDC labeler segment; a packager may place tablets into a different container; a distributor may market the finished package; and the plant that physically manufactures the drug can be another establishment. Avoid assuming all names identify the same firm.
The FDA NDC Directory contains submissions from labelers, including name, dosage form, route, strength and relevant marketing fields. FDA cautions that its inclusion alone does not establish agency approval or verification of each assertion. An NDC also is not a guarantee that an individual pharmacy has the product.
DailyMed structured labeling can identify the specific capsule or tablet, formulation, strength and the listed product companies. When a pharmacy provides an NDC, confirm that the current pack description and label correspond to the actual prescription. Packaging and repackaging records must not be mistaken for formulation-level sameness.
Match the source to the information you actually need.
| Source | Useful for | Not proof of |
|---|---|---|
| FDA NDC Directory | Submitted labeler and marketed product attributes | Approval or current retail stock |
| DailyMed | Structured full product labeling | That a listed item is on a shelf |
| FDA Orange Book | Approved applications and equivalence ratings | A particular wholesale shipment |
| Dispensing pharmacy | Exact intended package and live fulfillment status | Regulatory approval by itself |
The FDA Orange Book is the appropriate source for identifying approved products and therapeutic-equivalence ratings where those ratings apply. A product appearing in an NDC file is not a shortcut around that review. For substitution, the pharmacy must verify the precise pharmaceutically equivalent item and governing state rules.
A 100 mg hyclate tablet, a 100 mg monohydrate capsule, a delayed-release branded tablet and Oracea 40 mg capsules need not share the same substitute options. Search by complete dosage-form identity rather than merely the molecule. This prevents shoppers from comparing companies that sell clinically different products.
A marketing start or end date, a published label, or a listed manufacturer does not establish live retail inventory. Changes in distribution agreements, repackage channels and local wholesalers can alter which products are supplied. Only the dispensing pharmacy can confirm whether an acceptable package is presently obtainable.
Capture the product's NDC, complete proprietary or nonproprietary name, strength, dosage form, route, labeler and any manufacturer disclosures on the package. Then cross-check DailyMed and Orange Book records. Treat commercial claims about 'best quality' or guaranteed sourcing as marketing unless supported by independently verifiable evidence.
The labeler segment of an NDC can correspond to a company whose role is repackaging or distributing rather than manufacturing the original finished tablets. The pharmacy carton and bottle label may therefore display different corporate names without signaling different active ingredients. To explain a particular product accurately, retain its NDC, packaging size and label revision, and compare the corresponding records. Do not convert a list of active labelers into a ranking of manufacturing plants or quality claims without independent evidence.
Specific companies may enter or leave the market, change contract packagers or discontinue a labeled package. For a page intended to remain useful beyond one inventory snapshot, teach readers how to verify the current product instead of presenting static claims about availability. A useful record includes date of verification, the approved application when identifiable, the product-specific form and the pharmacy's current ability to obtain it. This is more reliable than announcing that a company always supplies a particular doxycycline capsule nationwide.
No. Labelers can include manufacturers, distributors, repackagers and other defined entities.
No. FDA expressly states that possession or inclusion of an NDC does not establish approval.
Yes. It provides submitted structured labeling that may identify form, composition, strength and company roles.
The FDA Orange Book is the principal starting point for approved products and therapeutic-equivalence information.
Do not assume so. The exact approved product and prescription need review.
No. Availability needs confirmation by the dispensing pharmacy.
Not without credible, relevant evidence. A verification guide is safer than invented rankings.